Artiva Biotherapeutics, Inc.
ARTV
$10.79
-$0.09-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.99% | 3.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.07% | 11.39% | |||
| Operating Income | -10.07% | -11.39% | |||
| Income Before Tax | -6.33% | -13.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.33% | -13.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.33% | -13.21% | |||
| EBIT | -10.07% | -11.39% | |||
| EBITDA | -10.24% | -11.75% | |||
| EPS Basic | 33.42% | -12.73% | |||
| Normalized Basic EPS | 33.43% | -3.37% | |||
| EPS Diluted | 33.42% | -12.73% | |||
| Normalized Diluted EPS | 33.43% | -3.37% | |||
| Average Basic Shares Outstanding | 59.71% | 0.43% | |||
| Average Diluted Shares Outstanding | 59.71% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||